NOVEL HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS WITH ANTICANCER ACTIVITY IN MEDULLOBLASTOMA

Abstract AIMS Medulloblastoma is the most common malignant brain tumor of childhood. Protein kinases are often overexpressed and constitute targets for the development of novel molecularly-targeted therapies in brain tumors. Here, we report the synthesis of new derivatives with kinase inhibitory act...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro-oncology (Charlottesville, Va.) Va.), 2024-10, Vol.26 (Supplement_7), p.vii6-vii6
Hauptverfasser: Roesler, Prof Rafael, Fortes, Ms Isadora Serraglio, Lopes, Dr Marcela, Brunetto, Dr André, de Farias, Dr Caroline Brunetto, Jaeger, Dr Mariane, Toson, Mr Bruno, de Andrade, Prof Saulo
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page vii6
container_issue Supplement_7
container_start_page vii6
container_title Neuro-oncology (Charlottesville, Va.)
container_volume 26
creator Roesler, Prof Rafael
Fortes, Ms Isadora Serraglio
Lopes, Dr Marcela
Brunetto, Dr André
de Farias, Dr Caroline Brunetto
Jaeger, Dr Mariane
Toson, Mr Bruno
de Andrade, Prof Saulo
description Abstract AIMS Medulloblastoma is the most common malignant brain tumor of childhood. Protein kinases are often overexpressed and constitute targets for the development of novel molecularly-targeted therapies in brain tumors. Here, we report the synthesis of new derivatives with kinase inhibitory activity and their anticancer activity in an early screening in medulloblastoma cells. METHOD The synthesis route was performed through six steps using a proper amino acid as starting material. The inhibitory activity of the final derivatives on the protein kinase was measured by fluorescence. Cultured DAOY medulloblastoma cells were used to examine anticancer activity. RESULTS The compounds display potent inhibitory activity on viability of DAOY medulloblastoma cells. The more promising derivative shows IC50 in the μM range in inhibiting the targeted protein kinase. CONCLUSION Further optimization of compounds in this series is currently being carried out. The encouraging preliminary results have revealed potential novel strategies for inhibiting kinase activity for the treatment of medulloblastoma.
doi_str_mv 10.1093/neuonc/noae158.021
format Article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_neuonc_noae158_021</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/neuonc/noae158.021</oup_id><sourcerecordid>10.1093/neuonc/noae158.021</sourcerecordid><originalsourceid>FETCH-LOGICAL-c811-393bb7ca9b731624e13923e487fcfabffb2e8a71dba8af29a8aa03b3183034573</originalsourceid><addsrcrecordid>eNqNkE1OwzAQRi0EEqVwAVa-QFr_NImzdF1DLJIYNW5RFyiygy2BoKkSdcHtCbQHYDPfLN4baT4A7jGaYZTR-d4fu30733fW45jNEMEXYIJjQqOYJcnl304iFuP0GtwMwwcaiTjBE_Ba6a0sYC6NXGuxE4USUOjyWW-qVQ15DZ9UxWsJVZWrpTJ6XcMXZXLIK6MEr4RcQy6M2iqzGxlYytWmKPSy4LXRJb8FV8F-Dv7unFNgHqQReVTox1EvopZhHNGMOpe2NnMpxQlZeEwzQv2CpaEN1oXgiGc2xW_OMhtINk6LqKOYUUQXcUqngJzOtn03DL0PzaF__7L9d4NR89tPc-qnOffTjN-PUnSSuuPhP_wPoApj3g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>NOVEL HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS WITH ANTICANCER ACTIVITY IN MEDULLOBLASTOMA</title><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Roesler, Prof Rafael ; Fortes, Ms Isadora Serraglio ; Lopes, Dr Marcela ; Brunetto, Dr André ; de Farias, Dr Caroline Brunetto ; Jaeger, Dr Mariane ; Toson, Mr Bruno ; de Andrade, Prof Saulo</creator><creatorcontrib>Roesler, Prof Rafael ; Fortes, Ms Isadora Serraglio ; Lopes, Dr Marcela ; Brunetto, Dr André ; de Farias, Dr Caroline Brunetto ; Jaeger, Dr Mariane ; Toson, Mr Bruno ; de Andrade, Prof Saulo</creatorcontrib><description>Abstract AIMS Medulloblastoma is the most common malignant brain tumor of childhood. Protein kinases are often overexpressed and constitute targets for the development of novel molecularly-targeted therapies in brain tumors. Here, we report the synthesis of new derivatives with kinase inhibitory activity and their anticancer activity in an early screening in medulloblastoma cells. METHOD The synthesis route was performed through six steps using a proper amino acid as starting material. The inhibitory activity of the final derivatives on the protein kinase was measured by fluorescence. Cultured DAOY medulloblastoma cells were used to examine anticancer activity. RESULTS The compounds display potent inhibitory activity on viability of DAOY medulloblastoma cells. The more promising derivative shows IC50 in the μM range in inhibiting the targeted protein kinase. CONCLUSION Further optimization of compounds in this series is currently being carried out. The encouraging preliminary results have revealed potential novel strategies for inhibiting kinase activity for the treatment of medulloblastoma.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/noae158.021</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>Neuro-oncology (Charlottesville, Va.), 2024-10, Vol.26 (Supplement_7), p.vii6-vii6</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Roesler, Prof Rafael</creatorcontrib><creatorcontrib>Fortes, Ms Isadora Serraglio</creatorcontrib><creatorcontrib>Lopes, Dr Marcela</creatorcontrib><creatorcontrib>Brunetto, Dr André</creatorcontrib><creatorcontrib>de Farias, Dr Caroline Brunetto</creatorcontrib><creatorcontrib>Jaeger, Dr Mariane</creatorcontrib><creatorcontrib>Toson, Mr Bruno</creatorcontrib><creatorcontrib>de Andrade, Prof Saulo</creatorcontrib><title>NOVEL HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS WITH ANTICANCER ACTIVITY IN MEDULLOBLASTOMA</title><title>Neuro-oncology (Charlottesville, Va.)</title><description>Abstract AIMS Medulloblastoma is the most common malignant brain tumor of childhood. Protein kinases are often overexpressed and constitute targets for the development of novel molecularly-targeted therapies in brain tumors. Here, we report the synthesis of new derivatives with kinase inhibitory activity and their anticancer activity in an early screening in medulloblastoma cells. METHOD The synthesis route was performed through six steps using a proper amino acid as starting material. The inhibitory activity of the final derivatives on the protein kinase was measured by fluorescence. Cultured DAOY medulloblastoma cells were used to examine anticancer activity. RESULTS The compounds display potent inhibitory activity on viability of DAOY medulloblastoma cells. The more promising derivative shows IC50 in the μM range in inhibiting the targeted protein kinase. CONCLUSION Further optimization of compounds in this series is currently being carried out. The encouraging preliminary results have revealed potential novel strategies for inhibiting kinase activity for the treatment of medulloblastoma.</description><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqNkE1OwzAQRi0EEqVwAVa-QFr_NImzdF1DLJIYNW5RFyiygy2BoKkSdcHtCbQHYDPfLN4baT4A7jGaYZTR-d4fu30733fW45jNEMEXYIJjQqOYJcnl304iFuP0GtwMwwcaiTjBE_Ba6a0sYC6NXGuxE4USUOjyWW-qVQ15DZ9UxWsJVZWrpTJ6XcMXZXLIK6MEr4RcQy6M2iqzGxlYytWmKPSy4LXRJb8FV8F-Dv7unFNgHqQReVTox1EvopZhHNGMOpe2NnMpxQlZeEwzQv2CpaEN1oXgiGc2xW_OMhtINk6LqKOYUUQXcUqngJzOtn03DL0PzaF__7L9d4NR89tPc-qnOffTjN-PUnSSuuPhP_wPoApj3g</recordid><startdate>20241015</startdate><enddate>20241015</enddate><creator>Roesler, Prof Rafael</creator><creator>Fortes, Ms Isadora Serraglio</creator><creator>Lopes, Dr Marcela</creator><creator>Brunetto, Dr André</creator><creator>de Farias, Dr Caroline Brunetto</creator><creator>Jaeger, Dr Mariane</creator><creator>Toson, Mr Bruno</creator><creator>de Andrade, Prof Saulo</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20241015</creationdate><title>NOVEL HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS WITH ANTICANCER ACTIVITY IN MEDULLOBLASTOMA</title><author>Roesler, Prof Rafael ; Fortes, Ms Isadora Serraglio ; Lopes, Dr Marcela ; Brunetto, Dr André ; de Farias, Dr Caroline Brunetto ; Jaeger, Dr Mariane ; Toson, Mr Bruno ; de Andrade, Prof Saulo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c811-393bb7ca9b731624e13923e487fcfabffb2e8a71dba8af29a8aa03b3183034573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roesler, Prof Rafael</creatorcontrib><creatorcontrib>Fortes, Ms Isadora Serraglio</creatorcontrib><creatorcontrib>Lopes, Dr Marcela</creatorcontrib><creatorcontrib>Brunetto, Dr André</creatorcontrib><creatorcontrib>de Farias, Dr Caroline Brunetto</creatorcontrib><creatorcontrib>Jaeger, Dr Mariane</creatorcontrib><creatorcontrib>Toson, Mr Bruno</creatorcontrib><creatorcontrib>de Andrade, Prof Saulo</creatorcontrib><collection>CrossRef</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roesler, Prof Rafael</au><au>Fortes, Ms Isadora Serraglio</au><au>Lopes, Dr Marcela</au><au>Brunetto, Dr André</au><au>de Farias, Dr Caroline Brunetto</au><au>Jaeger, Dr Mariane</au><au>Toson, Mr Bruno</au><au>de Andrade, Prof Saulo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NOVEL HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS WITH ANTICANCER ACTIVITY IN MEDULLOBLASTOMA</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2024-10-15</date><risdate>2024</risdate><volume>26</volume><issue>Supplement_7</issue><spage>vii6</spage><epage>vii6</epage><pages>vii6-vii6</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>Abstract AIMS Medulloblastoma is the most common malignant brain tumor of childhood. Protein kinases are often overexpressed and constitute targets for the development of novel molecularly-targeted therapies in brain tumors. Here, we report the synthesis of new derivatives with kinase inhibitory activity and their anticancer activity in an early screening in medulloblastoma cells. METHOD The synthesis route was performed through six steps using a proper amino acid as starting material. The inhibitory activity of the final derivatives on the protein kinase was measured by fluorescence. Cultured DAOY medulloblastoma cells were used to examine anticancer activity. RESULTS The compounds display potent inhibitory activity on viability of DAOY medulloblastoma cells. The more promising derivative shows IC50 in the μM range in inhibiting the targeted protein kinase. CONCLUSION Further optimization of compounds in this series is currently being carried out. The encouraging preliminary results have revealed potential novel strategies for inhibiting kinase activity for the treatment of medulloblastoma.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/neuonc/noae158.021</doi></addata></record>
fulltext fulltext
identifier ISSN: 1522-8517
ispartof Neuro-oncology (Charlottesville, Va.), 2024-10, Vol.26 (Supplement_7), p.vii6-vii6
issn 1522-8517
1523-5866
language eng
recordid cdi_crossref_primary_10_1093_neuonc_noae158_021
source Oxford University Press Journals All Titles (1996-Current)
title NOVEL HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS WITH ANTICANCER ACTIVITY IN MEDULLOBLASTOMA
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T18%3A04%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NOVEL%20HETEROCYCLIC%20COMPOUNDS%20AS%20KINASE%20INHIBITORS%20WITH%20ANTICANCER%20ACTIVITY%20IN%20MEDULLOBLASTOMA&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Roesler,%20Prof%20Rafael&rft.date=2024-10-15&rft.volume=26&rft.issue=Supplement_7&rft.spage=vii6&rft.epage=vii6&rft.pages=vii6-vii6&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/noae158.021&rft_dat=%3Coup_cross%3E10.1093/neuonc/noae158.021%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/neuonc/noae158.021&rfr_iscdi=true